How Long Does Wegovy Take to Work? (Before and After Pictures)

Wegovy has shown significant results, with numerous success stories. 

This article shares real user experiences and insights into Wegovy’s effectiveness and timeline for effects. Continue reading to learn how quickly people see results on Wegovy.

How Does Wegovy Work?

Wegovy mimics the body’s innate production of the hormone GLP-1 following a meal. This hormone regulates appetite, increases feelings of fullness, and slows gastric emptying, allowing you to feel satisfied with smaller food portions. 

Weekly Wegovy injections help to reduce food intake by signaling to the brain that you are full, which reduces hunger cravings. It also signals the pancreas to release insulin and decrease glucagon release. As a result, the glucose levels in your blood improves and so does fat burning.

Many users experience improved metabolic health, highlighting the overall health benefits alongside weight loss. Regular exercise and a balanced, calorie-reduced diet are often necessary for successful weight loss on Wegovy.

Wegovy is more effective compared to Saxenda, a once-daily, self-injectable medicine. However, it is less effective than the alternatives to Mounjaro.

How Long Does Wegovy Take to Work?

Wegovy’s contribution to better health is quite noteworthy. However, it is a gradual process. The timeline may vary depending on how individuals’ bodies respond to Wegovy. Also, progress is tied to the time needed to increase doses and improve your lifestyle habits.

Short-Term Results

The immediate effect of Wegovy therapy is appetite reduction. Aside from that, losing weight can start as early as 4 weeks post-therapy (around 2%). It can take several months to show visible changes in weight loss. 

During this time, users may experience potential side effects. During the first month, the dosage is typically gradually increased. This approach is intended to improve tolerability while minimizing side effects.

Trials revealed that patients lost approximately 6.7 kg at 3 months, equivalent to 5.9% of weight lost. After 20 weeks, people reaching the maintenance dose of 2.4 mg had reduced their mean body weight from 107.2 kg to 96.1 kg. Remarkably, patients placed on a placebo after 20 weeks of Wegovy treatment gained around 6.9% (about 6 kg) of their body weight.

Long-Term Results

Wegovy has noteworthy long-term results if you take them consistently following your doctor’s advice. 

A study by Novo Nordisk revealed that after 48 weeks of treatment with the highest dose of Wegovy, participants achieved an additional average weight loss of 7.9% from a baseline weight of 96.1 kg. At the 6-month mark, participants had lost an average of 12.3 kg, or 10.9% of their initial body weight. 

Certain people who received Wegovy 2.4 mg for 68 weeks achieved a total weight loss of 17.4%. Nonetheless, an average of 14.9% is to be expected. After two years on Wegovy, a third of people had dropped 20% or more of their starting weight.

Real Experiences: Wegovy Before and After Pictures

Here are some real photos of Wegovy users who have seen gradual progress over a year. These photos highlight the fat reduction around the body and depict how much weight is lost over time. 

Common Side Effects of Wegovy

Wegovy’s most frequent side effects are related to the stomach and include:

• Nausea 

• Diarrhea 

• Vomiting 

• Constipation 

• Abdominal pain

For most people, stomach side effects lessen or disappear after a few weeks of treatment. Wegovy is linked to a higher risk of bowel obstruction, gastroparesis, and pancreatitis.

Key Takeaways

• Wegovy is highly effective.

• Results after taking Wegovy are expected within the first three months on Wegovy. 

• Despite its mild gastrointestinal side effects, Wegovy is generally regarded as safe.

Frequently Asked Questions

Is Wegovy Safe Long Term?
Yes, Wegovy is safe long-term, apart from the minimal risk of gallbladder disease, pancreatitis, acute kidney injury, increased heart rate, diabetic retinopathy, mental health issues, and potentially thyroid cancer.

What is the Full Price of Wegovy?
The list price for Wegovy is CAD 63.51 per carton of 4 pre-filled, single-dose pens, regardless of strength (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, or 2.4 mg). However, the total price varies depending on your location, insurance coverage, and pharmacy. 

Sources:

• Wegovy

• FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight

• FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014

• Cadth. “Semaglutide (Wegovy).” Canadian Journal of Health Technologies (2022). https://doi.org/10.51731/cjht.2022.463.

• Villela, R., & Correa, R. (2021). Semaglutide 2.4 mg: the latest GLP-1RA approved for obesity. Journal of Investigative Medicine, 70, 3 – 4. https://doi.org/10.1136/jim-2021-002227.

• Singh, G., Krauthamer, M., & Bjalme-Evans, M. (2021). Wegovy (semaglutide): a new weight loss drug for chronic weight management. Journal of Investigative Medicine, 70, 5 – 13. https://doi.org/10.1136/jim-2021-001952.

• Mahase, E. (2023). GLP-1 agonists linked to adverse gastrointestinal events in weight loss patients. BMJ, 383. https://doi.org/10.1136/bmj.p2330.

• Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183

• Smits, M. M., & Van Raalte, D. H. (2021). Safety of Semaglutide. Frontiers in endocrinology, 12, 645563. https://doi.org/10.3389/fendo.2021.645563

• Semaglutide 2.4 mg demonstrates superior and sustained weight loss versus placebo and in addition a 17.4% weight loss after 68 weeks in STEP 4 trial

• Ghusn, W., De la Rosa, A., Sacoto, D., Cifuentes, L., Campos, A., Feris, F., Hurtado, M. D., & Acosta, A. (2022). Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity. JAMA network open, 5(9), e2231982. https://doi.org/10.1001/jamanetworkopen.2022.31982

• The Lancet (2024). Treating obesity and diabetes: drugs alone are not enough. Lancet (London, England), 403(10421), 1. https://doi.org/10.1016/S0140-6736(24)00003-5